The Pharma Data

JUNE 25, 2025

The interim data, presented at the SMA Research & Clinical Care Meeting hosted by Cure SMA in Anaheim, California, offer a strong signal of therapeutic potential. Strategic Collaboration with Ionis Pharmaceuticals Salanersen originated from Biogen’s longstanding collaboration with Ionis Pharmaceuticals, Inc. ,

Therapies 52

Therapies Trials RNA Treatment 52

BioPharma Drive: Drug Pricing

JULY 8, 2025

Multiple deals have been struck by large companies such as Roche and Novartis, suggesting pharmaceutical firms believe degraders have only begun to show their promise. SOURCE: Companies What’s next for targeted protein degradation?

Targeted Protein Degradation 145

Targeted Protein Degradation Small Molecule Disease Therapies 145

Drug Patent Watch

JANUARY 14, 2025

In the fast-paced world of pharmaceuticals, negotiations play a pivotal role in shaping the industry’s landscape. Let’s dive into the intricacies of pharmaceutical negotiations, exploring valuable lessons, current trends, and strategies for success.

Pharmaceuticals 54

Pharmaceuticals Compliance Licensing Licensing 54

The Pharma Data

JUNE 15, 2025

Sanofi and Regeneron’s Dupixent Shows Superiority over Xolair in First-Ever Head-to-Head Phase 4 Study in Patients with Severe Chronic Rhinosinusitis with Nasal Polyps and Co-existing Asthma Sanofi and Regeneron Pharmaceuticals, Inc.

Treatment 40

Treatment Clinical Trials Disease Trials 40

Drug Target Review

FEBRUARY 10, 2025

This circular process presents unique challenges, but the model Bock has developed at CTMC is tailored to overcome these hurdles efficiently. Dr. Bock has previously held leadership roles at MD Anderson, Teva Pharmaceuticals, CoGenesys, and Human Genome Sciences.

Therapies 64

Therapies Treatment Engineering Clinical Trials 64

Drug Target Review

JUNE 16, 2025

In this article, Stephan Schann, Chief Scientific Officer at Domain Therapeutics , explains why this class of drug target is so useful despite the challenges they present. However, due to its unique biology and structural complexity, PAR2 has proven notoriously difficult for the pharmaceutical industry to effectively target.

Disease 59

Disease Therapies Small Molecule Immune Response 59

The Pharma Data

JUNE 22, 2025

Engineered by Chugai Pharmaceutical Co., The Phase I/II data presented at the ISTH 2025 Congress mark a significant development in the journey of NXT007. The results from the Phase I/II NXTAGE trial, announced during the 2025 International Society on Thrombosis and Haemostasis (ISTH) Congress in Washington, D.C.,

Clinical Trials 40

Clinical Trials Therapies Treatment Trials 40

Drug Target Review

JULY 18, 2025

Scientific recognition at AACR This momentum was on full display at the AACR Annual Meeting, where Domain presented new preclinical and early clinical findings. Presenting our data at the AACR was an incredibly rewarding experience,” says Schann. Stephan holds a PhD in medical chemistry from University of Strasbourg in France.

Medical Chemistry 52

Medical Chemistry Small Molecule Therapies Clinical Development 52

The Pharma Data

JUNE 18, 2025

Data from that trial, presented at both the 2022 and 2023 European Society for Medical Oncology (ESMO) Congresses , demonstrated promising anti-tumor activity and a manageable safety profile in heavily pretreated patients with mCRPC.

Trials 40

Trials Therapies Clinical Trials Treatment 40

New Drug Approvals

JULY 9, 2025

1] History Sunvozertinib is being developed by Dizal Pharmaceutical. [5] In clinical settings, sunvozertinib has shown promising efficacy, with ongoing trials further assessing its utility as a targeted intervention for individuals presenting specific EGFR mutations. The reaction was quenched by H 2 O (0.1 yield) as an off-white solid.

FDA 62

FDA FDA Approval Clinical Trials Trials 62

The Pharma Data

JUNE 23, 2025

As the Phase 3 MARITIME program gets underway, the pharmaceutical and medical communities will be watching closely to see if Amgen’s investigational agent can deliver on its early promise—and potentially reshape the standard of care for the millions affected by obesity worldwide.

Trials 40

Trials Treatment Pharmacokinetics Clinical Trials 40

Drug Target Review

JUNE 6, 2025

End-to-end development Unlike many organisations in the pharmaceutical sector, RadioMedix maintains an integrated model from pre-clinical development through to commercial manufacturing. These measures ensure both the efficacy and safety of the final product.

Therapies 100

Therapies Treatment Drug Development Clinical Development 100

The Premier Consulting Blog

NOVEMBER 6, 2024

However, these products present unique challenges from a Chemistry, Manufacturing, and Controls (CMC) standpoint. As the prevalence of respiratory diseases continues to rise, the development of ICPs plays a pivotal role in addressing both clinical and patient-centered needs.

Production 52

Production FDA Compliance Disease 52

The Pharma Data

JUNE 6, 2025

Quality of Life and Pediatric Benefits: Insights from Phase 3 Trials In addition to the pooled sweat chloride analysis, Vertex presented a post hoc evaluation of Phase 3 trials focused specifically on ALYFTREK’s impact on patient-reported outcomes.

Therapies 40

Therapies Treatment Trials Clinical Trials 40

The Pharma Data

JUNE 20, 2025

The updated data, drawn from the Phase 1/2 segment of the larger Phase 1/2/3 FORWARD-101 clinical program, were unveiled during a high-profile oral presentation at the 85th Scientific Sessions of the American Diabetes Association (ADA) held in Chicago. The presentation at the ADA meeting was delivered by Dr. Michael R. Rickels, M.D.,

Therapies 40

Therapies Treatment Trials Production 40

The Pharma Data

JUNE 6, 2025

Otsuka Unveils Promising Phase 3 Results for Sibeprenlimab in IgA Nephropathy, Marking Significant Proteinuria Reduction and Advancing a Novel APRIL-Targeted Therapy Otsuka Pharmaceutical Development & Commercialization, Inc., in collaboration with Otsuka Pharmaceutical Co.,

Trials 40

Trials Treatment FDA Therapies 40

Drug Target Review

DECEMBER 16, 2024

Being a woman and an immigrant presented challenges in my professional growth along the way. Pooja transitioned to the pharmaceutical industry to broaden her impact on patient care, leveraging her expertise to help develop innovative cancer treatments. It took perseverance, hard work, and overcoming self-doubt to build credibility.

Medical Schools 52

Medical Schools Clinical Research Drug Development Trials 52

New Drug Approvals

JUNE 14, 2025

Compound 1 [0022] As defined above, a pharmaceutical composition of the present invention is a micronized powder comprising Compound 1. Preparation of Compound 1 [0023] In some embodiments, the pharmaceutical composition is a micronized powder comprising dry microparticles of Compound 1.

Clinical Development 62

Clinical Development Pharmaceuticals International 62

SugarCone Biotech

JUNE 19, 2025

Finally, while there are clear front runners among the pharmaceutical companies developing targeted therapeutics for these antigens there are also emerging biotechs aggressively pursuing these targets. Each target and each therapeutic modality induce varying degrees of clinical efficacy, as well as causing toxicities.

Therapies 78

Therapies Clinical Trials Treatment Clinical Development 78

DrugBank

JUNE 18, 2025

While these regulations protect public health, they also introduce significant challenges for pharmaceutical researchers. This means pharmaceutical companies must remain vigilant and adaptable to comply with evolving regulations. The extensive data requirements for regulatory submissions further complicate the process.

Drug Development 52

Drug Development Clinical Trials Compliance Drugs 52

Broad Institute

NOVEMBER 25, 2024

As a proof of concept, a drug designed to target a newly discovered biological node is showing efficacy in treating rare genetic diseases in the kidney, the eye, and the brain and is now making its way to clinical trials in collaboration with a pharmaceutical partner.

Clinical Trials 52

Clinical Trials Disease Trials Therapies 52

thought leadership

FEBRUARY 10, 2025

For pharmaceutical companies, this shift presents both challenges and opportunities. In today's digital age, social media has transformed how businesses communicate with their audiences. Social media can significantly enhance brand visibility and patient engagement and have an impact on the overall healthcare sector.

Pharmaceutical Companies 66

Pharmaceutical Companies Pharmaceuticals Production 66

Drug Patent Watch

DECEMBER 10, 2024

India: Balancing Innovation and Access India’s approach to patent thickets is influenced by its focus on balancing innovation with public health concerns: Stricter patentability criteria: India has stricter standards for pharmaceutical patents, potentially reducing thickets in this sector.

Licensing 98

Licensing Licensing International Marketing 98

PPD

DECEMBER 16, 2024

Each region presents its own set of unique and complex regulations that must be met, creating a daunting landscape for companies striving to bring their therapies to market. By doing so, sponsors can enhance their chances of success in todays competitive pharmaceutical market.

Drug Development 52

Drug Development Clinical Trials Compliance Trials 52

BioPharma Drive: Drug Pricing

JULY 14, 2025

and elsewhere in its 2025 fiscal year and plans to present detailed results at an upcoming medical meeting. Takeda will file an approval application in the U.S. The results position Takeda as the first company to seek approval of a narcolepsy drug that works by stimulating proteins called orexin receptors. There have been some setbacks.

Drugs 188

Drugs Clinical Trials Therapies Licensing 188

The Pharma Data

JUNE 25, 2025

These sustainability considerations align with growing global demand for environmentally responsible pharmaceutical manufacturing and distribution. BeOne Medicines’ decision to incorporate these factors into the BRUKINSA product lifecycle reflects the company’s commitment to corporate responsibility and long-term operational resilience.

Packaging 52

Packaging Marketing Pharmacokinetics Therapies 52

Elrig

MARCH 25, 2025

In addition, the conference comprises poster presentations, networking sessions, a vendor exhibition and a tour of AstraZenecas R&D centre. Prof Johnsons keynote presentation on day one will focus on Genomics-powered lncRNA therapeutics for oncology.

RNA 59

RNA Bioinformatics Science Pharmacokinetics 59

Drug Target Review

JUNE 14, 2025

I began developing my own scripts to streamline processes, which led me into scientific informatics, where I worked with pharmaceutical companies on cheminformatics. This year, following a presentation by the Aligned Foundation, we discussed ways to foster better collaboration between lab scientists and data scientists.

Laboratories 69

Laboratories Science Bioinformatics Molecular Biology 69

New Drug Approvals

JUNE 11, 2025

2] Gepirone was synthesized by Bristol-Myers Squibb in 1986 and was developed and marketed by Fabre-Kramer Pharmaceuticals. [4] Jump up to: a b c d e “Gepirone – Fabre-Kramer Pharmaceuticals” AdisInsight. 1] It is taken orally. [1] 1] Gepirone acts as a partial agonist of the serotonin 5-HT 1A receptor. [1]

FDA 62

FDA FDA Approval Treatment Clinical Trials 62

New Drug Approvals

APRIL 25, 2025

The difluoromethyl group can interact with the hydroxyl group presented on Ser774 (conserved) in p110, which is 3.2 “An Overview of Bioactive 1,3-Oxazole-Containing Alkaloids from Marine Organisms” Pharmaceuticals. nearer than of which on the equivalent residue Ser754 in p110. PMID 34127844. MDPI AG: 1274. PMC 8706051.

FDA 57

FDA FDA Approval Therapies Trials 57

The Pharma Data

JUNE 9, 2025

The results were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting , where they generated significant attention among oncologists, rheumatologists, and musculoskeletal disease experts.

Treatment 40

Treatment Therapies Small Molecule Marketing 40

Drug Target Review

JUNE 5, 2025

Studies presented at the American Society of Hematology 2024 Annual Meeting have predicted that patients receiving regular aRBCX would save up to $100,000 per patient lifetime to the healthcare system compared to other transfusion modalities, while increasing quality of life. JAMA Network Open. 2023;6(11) Newman TV, Yang J, Haubner A, et al.

Disease 52

Disease Treatment Therapies Nurses 52

The Pharma Data

JULY 2, 2025

BioMarin Finalizes Acquisition of Inozyme Pharma, Strengthening Rare Disease Portfolio with INZ-701 BioMarin Pharmaceutical Inc. Affected individuals may present with symptoms in infancy or early childhood, and the disease is associated with high morbidity and mortality.

Therapies 40

Therapies Disease Clinical Development Treatment 40

The Premier Consulting Blog

JANUARY 14, 2025

The summary presented in the table below features some of these initiatives. These resources provide accurate and current strategies that strongly represent FDAs standpoint and have routinely been leveraged by Premiers team of strategists when guiding sponsors through their development plans. Program What is it?

Clinical Trials 52

Clinical Trials Therapies FDA Trials 52

Drug Patent Watch

DECEMBER 16, 2024

However, there are several reasons why relying solely on Google Patents can be risky, especially in the context of pharmaceutical patents. Anticompetitive Effects Pharmaceutical patents, in general, have been criticized for their anticompetitive effects. Q: What are the anticompetitive effects of pharmaceutical patents?

Drugs 52

Drugs Pharmaceuticals Marketing Research 52

Conversations in Drug Development Trends

OCTOBER 29, 2024

Increasingly, patients and patient-led organizations are playing a pivotal role in shaping drug development, underscoring the importance of collaboration between patient organizations, CROs, and pharmaceutical and biotechnology companies.

Clinical Research 72

Clinical Research Disease Research Clinical Trials 72

Drug Patent Watch

DECEMBER 11, 2024

” – Dr. Jane Smith, Regulatory Affairs Expert at GeneriCorp Leveraging PSGs for Competitive Advantage To fully capitalize on the opportunities presented by PSGs, generic drug manufacturers must adopt a strategic approach to their use. This could lead to more efficient global development programs for generic drugs.

Drug Development 86

Drug Development Production FDA Drugs 86